References
- Lader M. Benzodiazepines revisited: Will we ever learn? Addiction 2011;106:2086–109.
- Available from: http://helsedirektoratet.no/sites/vanedannende-legemidler/Sider/default.aspx, accessed January 2015.
- Available from: http://www.rcpsych.ac.uk/healthadvice/treatmentswellbeing/benzodiazepines.aspx, accessed January 2015.
- Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs 2004;18:37–48.
- Lader M. Effectiveness of benzodiazepines: Do they work or not? Expert Rev Neurother 2008; 8:1189–91.
- Ashton H. Adverse effects of prolonged benzodiazepine use. Adverse Drug React Bull 1986;118:1–7.
- Smith RG. Fall-contributing adverse effects of the most frequently prescribed drugs. J Am Podiatr Med Assoc 2003;93:42–50.
- Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;24:1331–6.
- Oster G, Huse DM, Adams SF, et al. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 1990;80:1467–70.
- The Norwegian Prescription Database. Available from: http://www.norpd.no, accessed June 2014.
- Statistics Norway http://www.ssb.no/, accessed June 2014.
- DDD. Available from: http://www.whocc.no/ddd/definition_and_general_considera/, accessed June 2014.
- Tvete I, Bjørner T, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing BMJ Open. Available from: http://dx.doi.org/10.1136/bmjopen-2013-003296
- Available from: http://www.regjeringen.no/upload/AD/publikasjoner/veiledninger_brosjyrer/2012/Trygdesysteme_2012_engelsk.pdf, accessed January 2015.
- R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/, accessed June 2014.
- Meira-Machado L, Cadarso-Suárez C, Gude F, and Araújo A. An R Package for Pointwise Nonparametric Estimation of Hazard Ratio Curves of Continuous Predictors. Computational and Mathematical Methods in Medicine, 2013, 1-11.
- Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: Pharmacokinetics, dependency, rebound and withdrawal. Can J Clin Pharmacol 1999;6:69–83.
- Greenblatt DJ, Allen MD, Shader RI. Diazepam disposition determinants. Clin Pharmacol Ther 1980;27:301–12.
- Breimer DD. Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. Br J Clin Pharmacol 1979;8:7–13.
- Amrein R, Eckert M, Haefeli H, Leishman B. Pharmacokinetic and clinical considerations in the choice of a hypnotic. Br J Clin Pharmacol 1983;16:5–10.
- Hofman EJ, Mathew SJ. Anxiety disorders: A comprehensive review of pharmacotherapies. Mt Sinai J Med 2008;75: 248–62.
- Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: A review. Prim Care Companion J Clin Psychiatry 2008;10:222–8.
- Cochrane Database of Systematic Review. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0011800/, accessed June 2014.
- Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, Chiamulera C, Zoli M. Nicotinic acetylcholine receptors in the mesolimbic pathway: Primary role of ventral tegmental area receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 2010;30:5311–25.
- Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: Underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009;78:756–65.